“Studying the radioprotective effect of coenzyme Q10 on dry mouth”

Study of the Radioprotective Effect of Coenzyme Q10 on Dry Mouth Following External Radiotherapy for Head and Neck Cancer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241223064141N1

Enrollment

Registered

2025-05-20

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xeostomia or Dry mouth. Dry mouth, unspecified

Interventions

Intervention 1: “Intervention group:” There are 35 Patients in Our Intervention Group who Take 100 mg of Q10 Tablets, which is an Anti-inflammatory and Antioxidant Drug and Does not Interfere with the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Outpatients with Head and Neck Cancer Patients Over 18 Years of Age Patients who were Previously Taking Q10 Medication should Discontinue the Medication for 5 Days before Entering the Study. The Occurrence of Dry Mouth Due to any of the Causes of Diabetes, Sjogren's Syndrome, and Sialadenitis were Excluded from the Study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Dry mouth Score on the “Xerostomia inventory Questionnaire”. Timepoint: Two Days Before the Start of the Intervention and The Last Day of Radiation Therapy. Method of measurement: “ Xerostomia Inventory Questionnaire “.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaha Khani

Yazd University of Medical Sciences

tahakhani471376@gmail.com+98 35 3822 9276

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026